Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

The biotech uses one of the world’s largest datasets and AI supercomputers to find new drugs, but continued losses and lack of commercial products keep risk levels high. Recursion Pharmaceuticals is a ...

So, you want to get good at LeetCode, especially using Java? It’s a common goal for a lot of us trying to land those tech jobs. This guide is all about helping you get there. We’ll go over how to ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Fibonacci sequences are sequences of numbers whose first two elements are 0, 1, and such that, starting from the third number, every element of the sequence is the sum of the previous two. They are of ...

Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...